Antibody Response Against SARS-CoV-2 in Dialysis Patients During COVID-19

Antistof Respons Mod SARS-CoV-2 Hos Dialysepatienter i Forbindelse Med COVID-19

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04367714

Acronym

COVCKD

Enrollment

300

Registered

2020-04-29

Start date

2020-03-15

Completion date

2021-12-01

Last updated

2020-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID, Terminal Renal Insufficiency

Keywords

COVID-19, CKD 5

Brief summary

Determination of IgM and IgG antibodies against SARS-CoV-2 in dialysis patients by continous monitoring in the period from March 2020 to december 2020

Detailed description

Blood samples are collected every 14 days

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Dialysis

Exclusion criteria

* Not willing to give consent

Design outcomes

Primary

Measure	Time frame	Description
AAntibody response	1 year	IgM and IgG against SARS-CoV-2

Countries

Denmark

Contacts

Primary ContactFrank Mose, MD

frchri@rm.dk+4528531257

Outcome results